Matthew Ros, See Remarks at Epizyme, Inc. (EPZM), sold 4,242 shares at $24.64 ($99K) on 2020-01-24, disclosed to the SEC on 2020-01-27.
Scheduled sale ($99k) by See Remarks under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $22.40 | 2,395 | $54K | 54.1% |
| 2 | $24.64 | 1,847 | $46K | 45.9% |
| Total | $23.38 avg | 4,242 | $99K | 100% |
| Filing → |
| EPZM | SELL | 2020-06-30 | $44K | — | Filing → |
| EPZM | SELL | 2020-06-22 | $4.7M | — | Filing → |
| EPZM | SELL | 2020-03-26 | $19K | — | Filing → |